Viking Therapeutics Inc (VKTX)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Its pipeline includes VK2809, an orally available and tissue- and receptor-subtype selective thyroid hormone receptor beta agonist being studied in Phase IIb trials for biopsy-confirmed non-alcoholic steatohepatitis and NAFLD. The company is also developing VK5211, an oral non-steroidal selective androgen receptor modulator in Phase II trials for recovery after non-elective hip fracture surgery, along with VK0612 for metabolic disorders and anemia. Additional programs include VK2735, a dual GLP-1 agonist in Phase 1 SAD/MAD testing, and VK0214, a TRß agonist being evaluated for X-linked adrenoleukodystrophy. Viking Therapeutics was incorporated in 2012 and is headquartered in San Diego, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VKTX
|
$28.36
|
-30.6% Downside
|
Overvalued
|
$94.45
|
131.2% Upside
|
Bargain
|
Weak
|
0.0%
|
October 28, 2026
|
8.6x
|
4.765 B
|
3.015 B
|
0.1%
|
97.5%
|
18.8
|
78.2%
|
